| http://www.w3.org/ns/prov#value | - Nanobodies directed against EGFR or IGF-IR, respectively, and (human) serum albumin, or Nanobodies fused to an Fc portion, all as described herein) have a half-life that is at least 1.5 times, preferably at least 2 times, such as at least 5 times, for example at least 10 times or more than 20 times, the half-life of the corresponding Nanobody of the invention.Also, any derivatives or polypeptides
|
